China's State Council issued Decree No. 834, granting sweeping powers to investigate and sanction foreign companies that threaten China’s industrial chain security, impacting Western biopharma heavily reliant on Chinese supply chains. This move signals China's intent to assert control over its growing biotech sector, now a major player in global drug innovation. Developers and tech professionals should monitor how this regulation affects international collaborations and supply chain strategies in the pharmaceutical industry.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



